SCN Biotech Newswire – Y‑mAbs Therapeutics (YMAB) – August 5, 2025

Y-Mabs Therapeutics Inc (YMAB)

$8.52

+$4.33(+103.34%)Today

1D5D1M6MYTD1Y5Ymax

Open8.53

Volume16.1M

Day Low4.23

Day High8.59

Year Low3.55

Year High16.11

SERB Pharmaceuticals to Acquire Y‑mAbs for $8.60/Share — 105% Premium Delivered

1. Major Acquisition Alert

Y‑mAbs Therapeutics has entered a definitive agreement to be acquired by SERB Pharmaceuticals in an all-cash transaction valued at approximately $412 million. Shareholders will receive $8.60 per share, a 105% premium over the August 4 closing price GlobeNewswire+13Y-mAbs Therapeutics, Inc.+13RTTNews+13.

The transaction has unanimous approval from the Y‑mAbs board and is expected to close by Q4 2025, following standard antitrust clearance and a tender offer period that begins by August 19, 2025 Y-mAbs Therapeutics, Inc.+2Stock Titan+2.

2. Pipeline & Strategic Rationale

The acquisition includes DANYELZA® (naxitamab‑gqgk) — the first FDA‑approved therapy for relapsed/refractory high‑risk neuroblastoma. SERB views DANYELZA as a strong fit within its rare oncology portfolio, which includes drugs like Voraxaze®, Vistogard®, and Xermelo® Y-mAbs Therapeutics, Inc.+9Y-mAbs Therapeutics, Inc.+9GlobeNewswire+9.

Y‑mAbs also offers a growing radiopharmaceutical R&D pipeline, including investigational assets such as GD2‑SADAand CD38‑SADA, based on its SADA Pretargeted Radioimmunotherapy platform Yahoo Finance+12Y-mAbs Therapeutics, Inc.+12Y-mAbs Therapeutics, Inc.+12.

3. Financial & Shareholder Activity

Y‑mAbs closed at approximately $8.53 on August 5—nearly matching the tender offer price and marking about a 100% intraday gain on the acquisition news Y-mAbs Therapeutics, Inc.+13RTTNews+13GlobeNewswire+13.

Stockholders representing around 16% of outstanding shares have already committed to the transaction via support agreements Y-mAbs Therapeutics, Inc.+1.

However, retail investors and stakeholders should note that The Ademi Firm has launched a shareholder investigation, questioning whether the deal delivers fair value and scrutinizing potential preferential terms for insiders or restrictive deal clauses PR Newswire.

4. SCN Strategic Insights

Exit at a Solid Premium: For long-term holders, $8.60 represents an attractive valuation given prior valuation levels.

Validated Pipeline: With DANYELZA embraced by SERB as a core product, Y‑mAbs’ therapeutic platform gains credibility and continuity.

Due Diligence Alert: Investors should carefully monitor the shareholder investigation and tender offer documents (Schedule TO / 14D‑9) for fairness and deal terms.

Innovation Value Intact: While the SADA radiopharmaceutical platform remains early-stage, SERB may leverage its commercial infrastructure to develop it further.

#YMAB #Y-mAbs #Y-mAbsTherapeutics #BiotechNews #Acquisition #SERBPharmaceuticals #DANYELZA #Neuroblastoma #Radiopharmaceuticals #TenderOffer #InvestorAlert #ShareholderInvestigation